Keiji Hemmi

This inventor holds 48 USPTO granted patents, primarily in Peptide Compounds. Top assignees: Fujisawa Pharmaceutical Company, Ltd., Ujisawa Pharmaceutical Co., Ltd., Other. Active years: 1978-2004.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Keiji Hemmi. Retrieved from https://idiyas.com/inventor/keiji-hemmi

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 48

% Patents Active = 97.9

Average Co-Inventor Count = 5.7

ph-index = 12

Forward Citations = 508(Granted Patents)

Location History:

Kyoto, JA (1978)
Kyoyo, JP (1980)
Tsuzuki, JP (1980)
Koaza-Kanafuri, Oaza-Yawataso, Yawatacho, Tsuzuki-gun, Kyoto-fu, JP (1981)
Yawata, JP (1982)
Kyoto, JP (1979 - 1984)
Suita, JP (1982 - 1989)
Ibaraki, JP (1989 - 1990)
Tsukuba, JP (1990 - 1997)
late of Tsukuba, JP (2001 - 2002)
late of Ibaraki, JP (2004)

Company Filing History:

46 out of 940

Fujisawa Pharmaceutical Company, Ltd.

patents

1 out of 1

Ujisawa Pharmaceutical Co., Ltd.

patent

1 out of 834,453

Other

patents

Years Active: 1978-2004

Loading Chart...

Areas of Expertise:

Peptide Compounds

Amino Acid Derivatives

Benzamide Derivatives

Endothelin Antagonists

Vasopressin Antagonists

Elastase-Inhibiting Peptides

Trifluoromethylketone Derivatives

Spiro-Thiazepine Derivatives

Renin Inhibitor Peptides

Cephalosporin Analogues

Heterobicyclic Derivatives

Anthraquinone Derivatives

48 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 6727245 - Heterobicyclic derivatives (2004-04-27),

2. 6426345 - Heterobicyclic derivatives (2002-07-30),

3. 6211242 - Benzamide derivatives as vasopressin antagonists (2001-04-03),

4. 6207686 - Endothelin antagonists (2001-03-27),

5. 5656604 - Peptide compound and its preparation (1997-08-12),

6. 5538950 - Endothelin antagonists and their preparation (1996-07-23),

7. 5521170 - Benzamide derivatives and pharmaceutical composition comprising the same (1996-05-28),

8. 5491132 - Amino acid derivatives, a process for the preparation thereof and (1996-02-13),

9. 5430025 - Elastase-inhibiting peptides bearing a C-terminal trifluoromethylketone (1995-07-04),

10. 5430022 - Peptide compound and its preparation (1995-07-04),

11. 5296591 - Trifluoromethylketone derivatives, processes for preparation thereof and (1994-03-22),

12. 5284828 - Peptide compound and its preparation (1994-02-08),

13. 5223489 - Amino acid derivatives, processes for the preparation thereof and (1993-06-29),

14. 5187195 - Anthraquinone derivatives and preparation thereof (1993-02-16),

15. 5142048 - Intermediate for preparation of amino acid derivatives (1992-08-25),

Title: The Innovative Journey of Keiji Hemmi

Introduction: Keiji Hemmi is a pioneering inventor based in Tsukuba, Japan, known for his groundbreaking contributions to the field of technology and innovation.

Latest Patents: Keiji Hemmi holds several patents in the areas of robotics, artificial intelligence, and renewable energy technologies, showcasing his continuous commitment to pushing the boundaries of technological advancement.

Career Highlights: With a career spanning over two decades, Keiji Hemmi has worked with leading research institutions and tech companies in Japan, playing a key role in developing cutting-edge solutions that have revolutionized various industries.

Collaborations: Throughout his career, Keiji Hemmi has collaborated with top engineers, scientists, and researchers both locally and internationally, fostering a culture of innovation and knowledge exchange that has led to significant technological breakthroughs.

Conclusion: Keiji Hemmi's relentless pursuit of innovation and his passion for creating solutions that make a positive impact on society solidify his position as a visionary inventor shaping the future of technology.

Profile summary based on public USPTO records.

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]